Moderate treadmill exercise prevents oxidative stress-induced anxiety-like behavior in rats.
Recent work has suggested correlation of oxidative stress with anxiety-like behavior. There also is evidence for anxiolytic effects of physical exercise. However, a direct role of oxidative stress in anxiety is not clear and a protective role of physical exercise in oxidative stress-mediated anxiety has never been addressed. In this study, we have utilized rats to test direct involvement of oxidative stress with anxiety-like behavior and have identified oxidative stress mechanisms likely involved in anxiolytic effects of physical exercise. Intraperitoneal injections at non-toxic dose of l-buthionine-(S,R)-sulfoximine (BSO), an agent that increases oxidative stress markers, increased anxiety-like behavior of rats compared to vehicle-treated control rats. Prior 2 weeks treatment with the antioxidant, tempol attenuated BSO-induced anxiety-like behavior of rats suggesting a role of oxidative stress in this phenomenon. Moreover, moderate treadmill exercise prevented BSO-induced anxiety-like behavior of rats and also prevented BSO-mediated increase in oxidative stress markers in serum, urine and brain tissue homogenates from hippocampus, amygdala and locus coeruleus. Thus increasing oxidative stress increases anxiety-like behavior of rats. Moreover, antioxidant or treadmill exercise training both reduce oxidative stress in the rat brain regions implicated in anxiety response and prevent anxiety-like behavior of rats.
Salim
Samina
S
Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA. ssalim@uh.edu
Sarraj
Nada
N
Taneja
Manish
M
Saha
Kaustuv
K
Tejada-Simon
Maria Victoria
MV
Chugh
Gaurav
G
D000221:Adaptation, Ocular / Q000187:drug effects / Q000502:physiology; D000704:Analysis of Variance; D000818:Animals; D001007:Anxiety / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D001921:Brain / Q000378:metabolism; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D003497:Cyclic N-Oxides / Q000494:pharmacology; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005080:Exercise Test / Q000379:methods*; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D005978:Glutathione / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology; D018384:Oxidative Stress; D010805:Physical Conditioning, Animal; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D013113:Spin Labels; D013997:Time Factors
D003497:Cyclic N-Oxides; D004791:Enzyme Inhibitors; D018696:Neuroprotective Agents; D013113:Spin Labels; C075750:8-epi-prostaglandin F2alpha; D008315:Malondialdehyde; D019328:Buthionine Sulfoximine; D015237:Dinoprost; D005978:Glutathione; C001803:tempol